Analyst Expectations for Iovance Biotherapeutics's Future
Portfolio Pulse from Benzinga Insights
In the last quarter, Iovance Biotherapeutics (NASDAQ:IOVA) received 4 bullish, 2 somewhat bullish, and 3 indifferent analyst ratings. The company's average 12-month price target is $23.56, up 17.8% from the previous average of $20.00.
May 30, 2023 | 1:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Iovance Biotherapeutics received positive analyst ratings in the last quarter, with an average 12-month price target of $23.56, up 17.8% from the previous average.
The article mentions that Iovance Biotherapeutics has received mostly positive analyst ratings in the last quarter, with an increased average 12-month price target. This indicates a positive outlook for the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100